Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16821619rdf:typepubmed:Citationlld:pubmed
pubmed-article:16821619lifeskim:mentionsumls-concept:C0013216lld:lifeskim
pubmed-article:16821619lifeskim:mentionsumls-concept:C0376358lld:lifeskim
pubmed-article:16821619pubmed:issue3Blld:pubmed
pubmed-article:16821619pubmed:dateCreated2006-7-6lld:pubmed
pubmed-article:16821619pubmed:abstractTextNo consensus exists regarding further therapy for the management of hormone-refractory prostate cancer. In this phase II study, the combination of Vinorelbine with 5-Fluorouracil and folinic acid (FLN regimen) was evaluated in patients with progressive or resistant disease after hormone therapy.lld:pubmed
pubmed-article:16821619pubmed:languageenglld:pubmed
pubmed-article:16821619pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16821619pubmed:citationSubsetIMlld:pubmed
pubmed-article:16821619pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16821619pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16821619pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16821619pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16821619pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16821619pubmed:statusMEDLINElld:pubmed
pubmed-article:16821619pubmed:issn0250-7005lld:pubmed
pubmed-article:16821619pubmed:authorpubmed-author:GoldhirschAAlld:pubmed
pubmed-article:16821619pubmed:authorpubmed-author:RoccaAAlld:pubmed
pubmed-article:16821619pubmed:authorpubmed-author:MateiVVlld:pubmed
pubmed-article:16821619pubmed:authorpubmed-author:AscioneGGlld:pubmed
pubmed-article:16821619pubmed:authorpubmed-author:NolèFFlld:pubmed
pubmed-article:16821619pubmed:authorpubmed-author:LocatelliMMlld:pubmed
pubmed-article:16821619pubmed:authorpubmed-author:ScardinoEElld:pubmed
pubmed-article:16821619pubmed:authorpubmed-author:SbanottoAAlld:pubmed
pubmed-article:16821619pubmed:authorpubmed-author:ZampinoM GMGlld:pubmed
pubmed-article:16821619pubmed:authorpubmed-author:VerriEElld:pubmed
pubmed-article:16821619pubmed:authorpubmed-author:VerweijFFlld:pubmed
pubmed-article:16821619pubmed:authorpubmed-author:CuriglianoGGlld:pubmed
pubmed-article:16821619pubmed:authorpubmed-author:DecobelliOOlld:pubmed
pubmed-article:16821619pubmed:issnTypePrintlld:pubmed
pubmed-article:16821619pubmed:volume26lld:pubmed
pubmed-article:16821619pubmed:ownerNLMlld:pubmed
pubmed-article:16821619pubmed:authorsCompleteYlld:pubmed
pubmed-article:16821619pubmed:pagination2375-80lld:pubmed
pubmed-article:16821619pubmed:meshHeadingpubmed-meshheading:16821619...lld:pubmed
pubmed-article:16821619pubmed:meshHeadingpubmed-meshheading:16821619...lld:pubmed
pubmed-article:16821619pubmed:meshHeadingpubmed-meshheading:16821619...lld:pubmed
pubmed-article:16821619pubmed:meshHeadingpubmed-meshheading:16821619...lld:pubmed
pubmed-article:16821619pubmed:meshHeadingpubmed-meshheading:16821619...lld:pubmed
pubmed-article:16821619pubmed:meshHeadingpubmed-meshheading:16821619...lld:pubmed
pubmed-article:16821619pubmed:meshHeadingpubmed-meshheading:16821619...lld:pubmed
pubmed-article:16821619pubmed:meshHeadingpubmed-meshheading:16821619...lld:pubmed
pubmed-article:16821619pubmed:meshHeadingpubmed-meshheading:16821619...lld:pubmed
pubmed-article:16821619pubmed:meshHeadingpubmed-meshheading:16821619...lld:pubmed
pubmed-article:16821619pubmed:meshHeadingpubmed-meshheading:16821619...lld:pubmed
pubmed-article:16821619pubmed:meshHeadingpubmed-meshheading:16821619...lld:pubmed
pubmed-article:16821619pubmed:meshHeadingpubmed-meshheading:16821619...lld:pubmed
pubmed-article:16821619pubmed:articleTitleVinorelbine-based chemotherapy in hormone-refractory prostate cancer.lld:pubmed
pubmed-article:16821619pubmed:affiliationDepartment of Medicine, European Institute of Oncology, 20141 Milan, Italy.lld:pubmed
pubmed-article:16821619pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16821619pubmed:publicationTypeClinical Triallld:pubmed